Trial Profile

Double-blind, placebo-controlled study to investigate safety, tolerability, immunogenicity and clinical efficacy of a specific immunotherapy combining allergen with CYT003-QbG10 (CYT005-AllQbG10) in adult patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Jul 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CYT 005 AllQbG10 (Primary) ; House dust mite allergy immunotherapy; Vaccines
Indications Hypersensitivity; Perennial allergic rhinitis; Rhinoconjunctivitis
Focus Therapeutic Use

01 May 2009 Additional lead investigator (Mueller P) identified as reported by ClinicalTrials.gov
10 Jul 2008 Status changed from in progress to completed, based on results data reported in Cytos media release.
21 Jun 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com